Search

Your search keyword '"Bengrine-Lefevre, Leila"' showing total 117 results
Start Over Author "Bengrine-Lefevre, Leila"
117 results on '"Bengrine-Lefevre, Leila"'

1. Neoadjuvant and adjuvant pembrolizumab in advanced high-grade serous carcinoma: the randomized phase II NeoPembrOV clinical trial

Author

Ray-Coquard, Isabelle L., Savoye, Aude-Marie, Schiffler, Camille, Mouret-Reynier, Marie-Ange, Derbel, Olfa, Kalbacher, Elsa, LeHeurteur, Marianne, Martinez, Alejandra, Cornila, Corina, Martinez, Mathilde, Bengrine Lefevre, Leila, Priou, Frank, Cloarec, Nicolas, Venat, Laurence, Selle, Frédéric, Berton, Dominique, Collard, Olivier, Coquan, Elodie, Le Saux, Olivia, Treilleux, Isabelle, Gouerant, Sophie, Angelergues, Antoine, Joly, Florence, and Tredan, Olivier

Published
2024
Full Text
View/download PDF

2. Surgical patterns of care of pancreatic cancer. A French population-based study

Author

Bara, S., Bouvier, A.M., Jooste, V., Alves, A., Bouvier, V., Seigneurin, A., Coureau, G., Molinié, F., Dalmeida, T., Grosclaude, P., Daubisse-Marliac, L., Defossez, G., Guizard, A.V., Lapôtre-Ledoux, B., Hammas, K., Nousbaum, J.B., Plouvier, S., Trétarre, B., Velten, M., Woronoff, A.S., Goebel, Guillaume, Jooste, Valérie, Molinie, Florence, Grosclaude, Pascale, Woronoff, Anne-Sophie, Alves, Arnaud, Bouvier, Véronique, Nousbaum, Jean-Baptiste, Plouvier, Sandrine, Bengrine-Lefevre, Leila, Rabel, Thomas, and Bouvier, Anne-Marie

Published
2024
Full Text
View/download PDF

3. Hepatic arterial oxaliplatin plus intravenous 5-fluorouracil and cetuximab for first-line treatment of colorectal liver metastases: A multicenter phase II trial

Author

Malka, David, Verret, Benjamin, Faron, Matthieu, Guimbaud, Rosine, Caramella, Caroline, Edeline, Julien, Galais, Marie-Pierre, Bengrine-Lefevre, Leïla, Smith, Denis, Dupont-Bierre, Eric, De Baere, Thierry, Goéré, Diane, Dartigues, Peggy, Lacroix, Ludovic, Boige, Valérie, Gelli, Maximiliano, Pignon, Jean-Pierre, and Ducreux, Michel

Published
2023
Full Text
View/download PDF

4. Paclitaxel with or without pazopanib for ovarian cancer relapsing during bevacizumab maintenance therapy: The GINECO randomized phase II TAPAZ study

Author

Joly, Florence, Fabbro, Michel, Berton, Dominique, Lequesne, Justine, Anota, Amélie, Puszkiel, Alicja, Floquet, Anne, Vegas, Hélène, Bourgeois, Hugues, Bengrine Lefevre, Leïla, You, Benoît, Pommeret, Fanny, Lortholary, Alain, Spaeth, Dominique, Hardy-Bessard, Anne-Claire, Abdeddaim, Cyril, Kaminsky-Forrett, Marie-Christine, Tod, Michel, Kurtz, Jean-Emmanuel, Del Piano, Francesco, Meunier, Jérôme, Raban, Nadia, Alexandre, Jérome, Mouret-Reynier, Marie-Ange, Ray-Coquard, Isabelle, Provansal Gross, Magali, and Brachet, Pierre-Emmanuel

Published
2022
Full Text
View/download PDF

9. Impact of therapeutic strategy on disease‐free and overall survival of early‐stage cervical cancer: Surgery alone versus preoperative radiation

Author

Mahiou, Katia, primary, Vincent, Laura, additional, Peignaux‐Casasnovas, Karine, additional, Costaz, Hélène, additional, Padeano, Marie‐Martine, additional, Amet, Alix, additional, Dabakuyo, Sandrine, additional, Mamguem Kamga, Ariane, additional, Bengrine‐Lefevre, Leila, additional, and Coutant, Charles, additional

Published
2023
Full Text
View/download PDF

10. Supplementary Table 2: Human primer sequences used for RT-qPCR analysis from Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX–Bevacizumab Drug Treatment Regimen

Author

Limagne, Emeric, primary, Euvrard, Romain, primary, Thibaudin, Marion, primary, Rébé, Cédric, primary, Derangère, Valentin, primary, Chevriaux, Angélique, primary, Boidot, Romain, primary, Végran, Frédérique, primary, Bonnefoy, Nathalie, primary, Vincent, Julie, primary, Bengrine-Lefevre, Leila, primary, Ladoire, Sylvain, primary, Delmas, Dominique, primary, Apetoh, Lionel, primary, and Ghiringhelli, François, primary

Published
2023
Full Text
View/download PDF

11. Supplementary Figure 6: mRNA relative expression of genes involved in immunosuppression from Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX–Bevacizumab Drug Treatment Regimen

Author

Limagne, Emeric, primary, Euvrard, Romain, primary, Thibaudin, Marion, primary, Rébé, Cédric, primary, Derangère, Valentin, primary, Chevriaux, Angélique, primary, Boidot, Romain, primary, Végran, Frédérique, primary, Bonnefoy, Nathalie, primary, Vincent, Julie, primary, Bengrine-Lefevre, Leila, primary, Ladoire, Sylvain, primary, Delmas, Dominique, primary, Apetoh, Lionel, primary, and Ghiringhelli, François, primary

Published
2023
Full Text
View/download PDF

12. Supplementary Figure 4: IFN-γ and IL-17A secretion by CCR6 and CXCR3 expressing CD4 T cells from Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX–Bevacizumab Drug Treatment Regimen

Author

Limagne, Emeric, primary, Euvrard, Romain, primary, Thibaudin, Marion, primary, Rébé, Cédric, primary, Derangère, Valentin, primary, Chevriaux, Angélique, primary, Boidot, Romain, primary, Végran, Frédérique, primary, Bonnefoy, Nathalie, primary, Vincent, Julie, primary, Bengrine-Lefevre, Leila, primary, Ladoire, Sylvain, primary, Delmas, Dominique, primary, Apetoh, Lionel, primary, and Ghiringhelli, François, primary

Published
2023
Full Text
View/download PDF

13. Supplementary Figure Legends from Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX–Bevacizumab Drug Treatment Regimen

Author

Limagne, Emeric, primary, Euvrard, Romain, primary, Thibaudin, Marion, primary, Rébé, Cédric, primary, Derangère, Valentin, primary, Chevriaux, Angélique, primary, Boidot, Romain, primary, Végran, Frédérique, primary, Bonnefoy, Nathalie, primary, Vincent, Julie, primary, Bengrine-Lefevre, Leila, primary, Ladoire, Sylvain, primary, Delmas, Dominique, primary, Apetoh, Lionel, primary, and Ghiringhelli, François, primary

Published
2023
Full Text
View/download PDF

14. Data from Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX–Bevacizumab Drug Treatment Regimen

Author

Limagne, Emeric, primary, Euvrard, Romain, primary, Thibaudin, Marion, primary, Rébé, Cédric, primary, Derangère, Valentin, primary, Chevriaux, Angélique, primary, Boidot, Romain, primary, Végran, Frédérique, primary, Bonnefoy, Nathalie, primary, Vincent, Julie, primary, Bengrine-Lefevre, Leila, primary, Ladoire, Sylvain, primary, Delmas, Dominique, primary, Apetoh, Lionel, primary, and Ghiringhelli, François, primary

Published
2023
Full Text
View/download PDF

15. Supplementary Figure 2: MDSC gating strategy and IL-4Rα expression analysis. from Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX–Bevacizumab Drug Treatment Regimen

Author

Limagne, Emeric, primary, Euvrard, Romain, primary, Thibaudin, Marion, primary, Rébé, Cédric, primary, Derangère, Valentin, primary, Chevriaux, Angélique, primary, Boidot, Romain, primary, Végran, Frédérique, primary, Bonnefoy, Nathalie, primary, Vincent, Julie, primary, Bengrine-Lefevre, Leila, primary, Ladoire, Sylvain, primary, Delmas, Dominique, primary, Apetoh, Lionel, primary, and Ghiringhelli, François, primary

Published
2023
Full Text
View/download PDF

16. Supplementary Figure 3: Blood parameters in Healthy Volunteers versus mCRC patients from Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX–Bevacizumab Drug Treatment Regimen

Author

Limagne, Emeric, primary, Euvrard, Romain, primary, Thibaudin, Marion, primary, Rébé, Cédric, primary, Derangère, Valentin, primary, Chevriaux, Angélique, primary, Boidot, Romain, primary, Végran, Frédérique, primary, Bonnefoy, Nathalie, primary, Vincent, Julie, primary, Bengrine-Lefevre, Leila, primary, Ladoire, Sylvain, primary, Delmas, Dominique, primary, Apetoh, Lionel, primary, and Ghiringhelli, François, primary

Published
2023
Full Text
View/download PDF

17. Supplementary Figure 1: THelper gating strategy from Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX–Bevacizumab Drug Treatment Regimen

Author

Limagne, Emeric, primary, Euvrard, Romain, primary, Thibaudin, Marion, primary, Rébé, Cédric, primary, Derangère, Valentin, primary, Chevriaux, Angélique, primary, Boidot, Romain, primary, Végran, Frédérique, primary, Bonnefoy, Nathalie, primary, Vincent, Julie, primary, Bengrine-Lefevre, Leila, primary, Ladoire, Sylvain, primary, Delmas, Dominique, primary, Apetoh, Lionel, primary, and Ghiringhelli, François, primary

Published
2023
Full Text
View/download PDF

18. Supplementary Table 1: Patient and Healthy volunteer's characteristics from Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX–Bevacizumab Drug Treatment Regimen

Author

Limagne, Emeric, primary, Euvrard, Romain, primary, Thibaudin, Marion, primary, Rébé, Cédric, primary, Derangère, Valentin, primary, Chevriaux, Angélique, primary, Boidot, Romain, primary, Végran, Frédérique, primary, Bonnefoy, Nathalie, primary, Vincent, Julie, primary, Bengrine-Lefevre, Leila, primary, Ladoire, Sylvain, primary, Delmas, Dominique, primary, Apetoh, Lionel, primary, and Ghiringhelli, François, primary

Published
2023
Full Text
View/download PDF

19. Supplementary Figure 5: Blood parameters in mCRC patients, D0 versus D15 from Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX–Bevacizumab Drug Treatment Regimen

Author

Limagne, Emeric, primary, Euvrard, Romain, primary, Thibaudin, Marion, primary, Rébé, Cédric, primary, Derangère, Valentin, primary, Chevriaux, Angélique, primary, Boidot, Romain, primary, Végran, Frédérique, primary, Bonnefoy, Nathalie, primary, Vincent, Julie, primary, Bengrine-Lefevre, Leila, primary, Ladoire, Sylvain, primary, Delmas, Dominique, primary, Apetoh, Lionel, primary, and Ghiringhelli, François, primary

Published
2023
Full Text
View/download PDF

20. Impact of complete surgical staging on survival of patients with early-stage (FIGO I or II) ovarian cancer: Data from the Cote d’Or Registry of Gynecological Cancers from 1998 to 2015

Author

Michel, Eloïse, primary, Mamguem Kamga, Ariane, additional, Amet, Alix, additional, Padeano, Marie-Martine, additional, Fumet, Jean-David, additional, Favier, Laure, additional, Bengrine Lefevre, Leila, additional, Beltjens, Françoise, additional, Arnould, Laurent, additional, Dabakuyo, Sandrine, additional, and Costaz, Hélène, additional

Published
2023
Full Text
View/download PDF

23. 2022-RA-177-ESGO Impact of therapeutic strategy on disease-free and overall survival of early stage cervical cancer: surgery aloneversuspre-operative radiotherapy

Author

Mahiou, Katia, primary, Vincent, Laura, additional, Peignaux-Casasnovas, Karine, additional, Costaz, Hélène, additional, Padeano, Marie-Martine, additional, Amet, Alix, additional, Dabakuyo, Sandrine, additional, Bengrine-Lefevre, Leila, additional, and Coutant, Charles, additional

Published
2022
Full Text
View/download PDF

24. Adapted physical activity in patients (Pts) with advanced pancreatic cancer (APACaP): Results from a prospective national randomized GERCOR trial.

Author

Neuzillet, Cindy, primary, Bouché, Olivier, additional, Tournigand, Christophe, additional, Chibaudel, Benoist, additional, Bouguion, Lucile, additional, Bengrine-Lefevre, Leila, additional, Lopez-Trabada Ataz, Daniel, additional, Mabro, May, additional, Metges, Jean-Philippe, additional, Péré-Vergé, Denis, additional, Conroy, Thierry, additional, Lievre, Astrid, additional, Andre, Morgan, additional, Desseigne, Françoise, additional, Goldwasser, François, additional, Henriques, Julie, additional, Anota, Amélie, additional, and Hammel, Pascal, additional

Published
2022
Full Text
View/download PDF

26. Cervical cancer in older women: Does age matter?

Author

Barben, Jérémy, primary, Kamga, Ariane Mamguem, additional, Dabakuyo-Yonli, Tienhan Sandrine, additional, Hacquin, Arthur, additional, Putot, Alain, additional, Manckoundia, Patrick, additional, Bengrine-Lefevre, Leila, additional, and Quipourt, Valérie, additional

Published
2022
Full Text
View/download PDF

27. Parallel evolution and differences in seroprevalence of SARS-CoV-2 antibody between patients with cancer and health care workers in a tertiary cancer centre during the first and second wave of COVID-19 pandemic: canSEROcov-II cross-sectional study

Author

Ladoire, Sylvain, primary, Rederstorff, Emilie, additional, Goussot, Vincent, additional, Parnalland, Sophie, additional, Briot, Nathalie, additional, Ballot, Elise, additional, Truntzer, Caroline, additional, Ayati, Siavoshe, additional, Bengrine-Lefevre, Leila, additional, Bremaud, Nathalie, additional, Coudert, Bruno, additional, Desmoulins, Isabelle, additional, Favier, Laure, additional, Fraisse, Cléa, additional, Fumet, Jean-David, additional, Hennequin, Audrey, additional, Hervieu, Alice, additional, Ilie, Silvia, additional, Kaderbhai, Courèche, additional, Lagrange, Aurélie, additional, Martin, Nils, additional, Mazilu, Irina, additional, Mayeur, Didier, additional, Palmier, Rémi, additional, Simonet-Lamm, Anne-Laure, additional, Vincent, Julie, additional, Zanetta, Sylvie, additional, Arnould, Laurent, additional, Coutant, Charles, additional, Bertaut, Aurélie, additional, and Ghiringhelli, François, additional

Published
2022
Full Text
View/download PDF

31. Phase I Dose-Escalation Trial of an Innovative Chemotherapy Regimen Combining a Fractionated Dose of Irinotecan Plus Bevacizumab, Oxaliplatin, 5-Fluorouracil, and Folinic Acid (bFOLFIRINOX-3) in Chemorefractory Metastatic Colorectal Cancer

Author

Bellio, Hélène, primary, Bertaut, Aurélie, additional, Hervieu, Alice, additional, Zanetta, Sylvie, additional, Hennequin, Audrey, additional, Vincent, Julie, additional, Palmier, Rémi, additional, Bengrine-Lefevre, Leila, additional, Ghiringhelli, François, additional, and Fumet, Jean-David, additional

Published
2021
Full Text
View/download PDF

32. Expression of a mutant HSP110 sensitizes colorectal cancer cells to chemotherapy and improves disease prognosis

Author

Dorard, Coralie, de Thonel, Aurelie, Collura, Ada, Marisa, Laetitia, Svrcek, Magali, Lagrange, Anais, Jego, Gaetan, Wanherdrick, Kristell, Joly, Anne Laure, Buhard, Olivier, Gobbo, Jessica, Penard-Lacronique, Virginie, Zouali, Habib, Tubacher, Emmanuel, Kirzin, Sylvain, Selves, Janick, Milano, Gerard, Etienne-Grimaldi, Marie-Christine, Bengrine-Lefevre, Leila, Louvet, Christophe, Tournigand, Christophe, Lefevre, Jeremie H., Parc, Yann, Tiret, Emmanuel, Flejou, Jean-Francis, Gaub, Marie-Pierre, Garrido, Carmen, and Duval, Alex

Subjects
Heat shock proteins -- Physiological aspects -- Genetic aspects -- Research, Colorectal cancer -- Genetic aspects -- Drug therapy -- Prognosis, Chemotherapy -- Physiological aspects -- Genetic aspects -- Research, Cancer -- Chemotherapy, Biological sciences, Health
Abstract

Heat shock proteins (HSPs) are necessary for cancer cell survival. We identified a mutant of HSP110 (HSP110δE9) in colorectal cancer showing microsatellite instability (MSI CRC), generated from an aberrantly spliced mRNA and lacking the HSP110 substrate-binding domain. This mutant was expressed at variable levels in almost all MSI CRC cell lines and primary tumors tested. HSP110ΔE9 impaired both the normal cellular localization of HSP110 and its interaction with other HSPs, thus abrogating the chaperone activity and antiapoptotic function of HSP110 in a dominant-negative manner. HSP110ΔE9 overexpression caused the sensitization of cells to anticancer agents such as oxaliplatin and 5-fluorouracil, which are routinely prescribed in the adjuvant treatment of people with CRC. The survival and response to chemotherapy of subjects with MSI CRCs was associated with the tumor expression level of HSP110ΔE9. HSP110 may thus constitute a major determinant for both prognosis and treatment response in CRC., The human tumor phenotype referred to as MSI arises because of defects in the DNA mismatch repair (MMR) system (1-3). MSI was first observed in inherited tumors associated with Lynch [...]

Published
2011
Full Text
View/download PDF

33. Seroprevalence of SARS-CoV-2 among the staff and patients of a French cancer centre after first lockdown: The canSEROcov study

Author

Ladoire, Sylvain, primary, Goussot, Vincent, additional, Redersdorff, Emilie, additional, Cueff, Adele, additional, Ballot, Elise, additional, Truntzer, Caroline, additional, Ayati, Siavoshe, additional, Bengrine-Lefevre, Leila, additional, Bremaud, Nathalie, additional, Coudert, Bruno, additional, Desmoulins, Isabelle, additional, Favier, Laure, additional, Fraisse, Cléa, additional, Fumet, Jean-David, additional, Hanu, Roxana, additional, Hennequin, Audrey, additional, Hervieu, Alice, additional, Ilie, Silvia, additional, Kaderbhai, Courèche, additional, Lagrange, Aurélie, additional, Martin, Nils, additional, Mazilu, Irina, additional, Mayeur, Didier, additional, Palmier, Rémi, additional, Simonet-Lamm, Anne-Laure, additional, Vincent, Julie, additional, Zanetta, Sylvie, additional, Arnould, Laurent, additional, Coutant, Charles, additional, Bertaut, Aurélie, additional, and Ghiringhelli, François, additional

Published
2021
Full Text
View/download PDF

35. Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de Cancérologie Digestive-PRODIGE 37 randomised phase II study (FIRGEMAX)

Author

Rinaldi, Yves, primary, Pointet, Anne-Laure, additional, Khemissa Akouz, Faiza, additional, Le Malicot, Karine, additional, Wahiba, Bidaut, additional, Louafi, Samy, additional, Gratet, Alain, additional, Miglianico, Laurent, additional, Laharie, Hortense, additional, Bouhier Leporrier, Karine, additional, Thirot Bidault, Anne, additional, Texereau, Patrick, additional, Coriat, Romain, additional, Terrebonne, Eric, additional, Gouttebel, Marie-Claude, additional, Malka, David, additional, Bachet, Jean-Baptiste, additional, Lepage, Côme, additional, Taieb, Julien, additional, Julien, Cécile, additional, Barriere, Nicolas, additional, Gigout, Julie, additional, Pernot, Simon, additional, Lepere, Céline, additional, Zaanan, Aziz, additional, Perkins, Géraldine, additional, Despax, Raymond, additional, Chamois, Jérôme, additional, Artignan, Xavier, additional, Regnault, Pauline, additional, Dupont, Benoît, additional, Lesouef, Maxime, additional, Bengrine Lefevre, Leila, additional, Vincent, Julie, additional, Ghiringhelli, François, additional, Barbier, Mme E., additional, Andre, Morgan, additional, Dreanic, Johann, additional, Brezault-Bonnet, Catherine, additional, Boige, Valérie, additional, Holllebecque, Antoine, additional, Valenza, Bruno, additional, Phelip, Gildas, additional, Dominici, Philippe, additional, Chauvenet, Marion, additional, Moryoussef, Frederick, additional, Etienne, Pierre-Luc, additional, Besson, Dominique, additional, Martinez, Mathilde, additional, Biondiani, Pamela, additional, Avisse, Benoît, additional, Galais, Marie-Pierre, additional, Parzy, Aurélie, additional, Caruso, Salvatore, additional, Codoul, Jean-François, additional, Pripon, Iulia, additional, Atlassi, Mustapha, additional, Cojocarasu, Oana, additional, Suc, Etienne, additional, Bedjaoui, Ahmed, additional, Houyau, Philippe, additional, Berge, Yann, additional, Gargot, Dany, additional, Bourgeois, Vincent, additional, Henneresse, Pierre-Emmanuel, additional, Lavau denes, Sandrine, additional, Lebrun Lyat, Valérie, additional, Genet, Dominique, additional, Martin, Jean, additional, Michel, Pr Pierre, additional, Sefrioui, David, additional, Escande, Anne, additional, and Dourthe, Louis-Marie, additional

Published
2020
Full Text
View/download PDF

37. Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomized Adjuvant Chemotherapy Trial

Author

Jones, Robert P, Psarelli, Eftychia-Eirini, Jackson, Richard, Ghaneh, Paula, Halloran, Christopher M, Palmer, Daniel H, Campbell, Fiona, Valle, Juan W, Faluyi, Olusola, O'Reilly, Derek A, Cunningham, David, Wadsley, Jonathan, Darby, Suzanne, Meyer, Tim, Gillmore, Roopinder, Anthoney, Alan, Lind, Pehr, Glimelius, Bengt, Falk, Stephen, Izbicki, Jakob R, Middleton, Gary William, Cummins, Sebastian, Ross, Paul J, Wasan, Harpreet, McDonald, Alec, Crosby, Tom, Ting, Yuk, Patel, Kinnari, Sherriff, David, Soomal, Rubin, Borg, David, Sothi, Sharmila, Hammel, Pascal, Lerch, Markus M, Mayerle, Julia, Tjaden, Christine, Strobel, Oliver, Hackert, Thilo, Buchler, Markus W, Neoptolemos, John P, Hill, Mark, Corrie, Pippa, Hickish, Tamas, Napier, Mark, Slater, Sarah, Valle, Juan, Shablak, Alaaeldin, Cunnell, Michelle, Guimbaud, Rosine, Roques, Tom, Iveson, Tim, Jamil, Arshad, Robinson, Angus, Garcia-Alonso, Angel, Chang, David, Tsang, David, Wadd, Nick, Wall, Lucy, Nielsen, Niels Hilmer, Lerch, Markus, Mehta, Ajay, Sivaramalingam, Muthiah, Fyfe, David, Osborne, Richard, Blesing, Claire, Bulusu, Venkata Ramesh, Rathbone, Emma, Seitz, Jean-Francois, Beaumont, Erica, Dernedde, Ulrike, McAdam, Karen, Dimopoulos, Prokopios, Cominos, Mathilda, Askill, Colin, Piwowar, Andrzej, Bachet, Jean-Baptiste, Sumpter, Kate, Raouf, Sherif, Nicoll, Jonathan, Rees, Charlotte, Dhinakaran, Kathirvelu, Haux, Johan, Bengrine-Lefevre, Leila, Terrebonne, Eric, Shankland, Catherine, Palmer, Cheryl, Medley, Louise, Toy, Elizabeth, Kaur, Jasvinder, Gupta, Kamalnayan, Cheeseman, Sue, Patterson, Daniel, Candish, Charles, Thompson, Joyce, Coxon, Fareeda, Connolly, Caroline, McPhail, Neil, Williams, Rachel, Flygare, Petra, Elmlund, Mattias, Artru, Pascal, Millat, Bertrand, and Canc, European Study Grp Pancreatic

Subjects
medicine.medical_specialty, Chemotherapy, Randomization, business.industry, medicine.medical_treatment, 030230 surgery, medicine.disease, Gastroenterology, Gemcitabine, law.invention, Capecitabine, 03 medical and health sciences, 0302 clinical medicine, Randomized controlled trial, law, 030220 oncology & carcinogenesis, Internal medicine, Pancreatic cancer, medicine, Carcinoma, Surgery, Prospective cohort study, business, medicine.drug
Abstract

Importance The patterns of disease recurrence after resection of pancreatic ductal adenocarcinoma with adjuvant chemotherapy remain unclear. Objective To define patterns of recurrence after adjuvant chemotherapy and the association with survival. Design, Setting, and Participants Prospectively collected data from the phase 3 European Study Group for Pancreatic Cancer 4 adjuvant clinical trial, an international multicenter study. The study included 730 patients who had resection and adjuvant chemotherapy for pancreatic cancer. Data were analyzed between July 2017 and May 2019. Interventions Randomization to adjuvant gemcitabine or gemcitabine plus capecitabine. Main Outcomes and Measures Overall survival, recurrence, and sites of recurrence. Results Of the 730 patients, median age was 65 years (range 37-81 years), 414 were men (57%), and 316 were women (43%). The median follow-up time from randomization was 43.2 months (95% CI, 39.7-45.5 months), with overall survival from time of surgery of 27.9 months (95% CI, 24.8-29.9 months) with gemcitabine and 30.2 months (95% CI, 25.8-33.5 months) with the combination (HR, 0.81; 95% CI, 0.68-0.98;P = .03). The 5-year survival estimates were 17.1% (95% CI, 11.6%-23.5%) and 28.0% (22.0%-34.3%), respectively. Recurrence occurred in 479 patients (65.6%); another 78 patients (10.7%) died without recurrence. Local recurrence occurred at a median of 11.63 months (95% CI, 10.05-12.19 months), significantly different from those with distant recurrence with a median of 9.49 months (95% CI, 8.44-10.71 months) (HR, 1.21; 95% CI, 1.01-1.45;P = .04). Following recurrence, the median survival was 9.36 months (95% CI, 8.08-10.48 months) for local recurrence and 8.94 months (95% CI, 7.82-11.17 months) with distant recurrence (HR, 0.89; 95% CI, 0.73-1.09;P = .27). The median overall survival of patients with distant-only recurrence (23.03 months; 95% CI, 19.55-25.85 months) or local with distant recurrence (23.82 months; 95% CI, 17.48-28.32 months) was not significantly different from those with only local recurrence (24.83 months; 95% CI, 22.96-27.63 months) (P = .85 andP = .35, respectively). Gemcitabine plus capecitabine had a 21% reduction of death following recurrence compared with monotherapy (HR, 0.79; 95% CI, 0.64-0.98;P = .03). Conclusions and Relevance There were no significant differences between the time to recurrence and subsequent and overall survival between local and distant recurrence. Pancreatic cancer behaves as a systemic disease requiring effective systemic therapy after resection. Trial Registration ClinicalTrials.gov identifier:NCT00058201, EudraCT 2007-004299-38, and ISRCTN 96397434.

Published
2019

38. Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma : A Secondary Analysis of the ESPAC-4 Randomized Adjuvant Chemotherapy Trial

Author

Jones, Robert P., Psarelli, Eftychia-Eirini, Jackson, Richard, Ghaneh, Paula, Halloran, Christopher M., Palmer, Daniel H., Campbell, Fiona, Valle, Juan W., Faluyi, Olusola, O'Reilly, Derek A., Cunningham, David, Wadsley, Jonathan, Darby, Suzanne, Meyer, Tim, Gillmore, Roopinder, Anthoney, Alan, Lind, Pehr, Glimelius, Bengt, Falk, Stephen, Izbicki, Jakob R., Middleton, Gary William, Cummins, Sebastian, Ross, Paul J., Wasan, Harpreet, McDonald, Alec, Crosby, Tom, Ting, Yuk, Patel, Kinnari, Sherriff, David, Soomal, Rubin, Borg, David, Sothi, Sharmila, Hammel, Pascal, Lerch, Markus M., Mayerle, Julia, Tjaden, Christine, Strobel, Oliver, Hackert, Thilo, Buchler, Markus W., Neoptolemos, John P., Hill, Mark, Corrie, Pippa, Hickish, Tamas, Napier, Mark, Slater, Sarah, Valle, Juan, Shablak, Alaaeldin, Cunnell, Michelle, Guimbaud, Rosine, Roques, Tom, Iveson, Tim, Jamil, Arshad, Robinson, Angus, Garcia-Alonso, Angel, Chang, David, Tsang, David, Wadd, Nick, Wall, Lucy, Nielsen, Niels Hilmer, Lerch, Markus, Mehta, Ajay, Sivaramalingam, Muthiah, Fyfe, David, Osborne, Richard, Blesing, Claire, Bulusu, Venkata Ramesh, Rathbone, Emma, Seitz, Jean-Francois, Beaumont, Erica, Dernedde, Ulrike, McAdam, Karen, Dimopoulos, Prokopios, Cominos, Mathilda, Askill, Colin, Piwowar, Andrzej, Bachet, Jean-Baptiste, Sumpter, Kate, Raouf, Sherif, Nicoll, Jonathan, Rees, Charlotte, Dhinakaran, Kathirvelu, Haux, Johan, Bengrine-Lefevre, Leila, Terrebonne, Eric, Shankland, Catherine, Palmer, Cheryl, Medley, Louise, Toy, Elizabeth, Kaur, Jasvinder, Gupta, Kamalnayan, Cheeseman, Sue, Patterson, Daniel, Candish, Charles, Thompson, Joyce, Coxon, Fareeda, Connolly, Caroline, McPhail, Neil, Williams, Rachel, Flygare, Petra, Elmlund, Mattias, Artru, Pascal, Millat, Bertrand, Jones, Robert P., Psarelli, Eftychia-Eirini, Jackson, Richard, Ghaneh, Paula, Halloran, Christopher M., Palmer, Daniel H., Campbell, Fiona, Valle, Juan W., Faluyi, Olusola, O'Reilly, Derek A., Cunningham, David, Wadsley, Jonathan, Darby, Suzanne, Meyer, Tim, Gillmore, Roopinder, Anthoney, Alan, Lind, Pehr, Glimelius, Bengt, Falk, Stephen, Izbicki, Jakob R., Middleton, Gary William, Cummins, Sebastian, Ross, Paul J., Wasan, Harpreet, McDonald, Alec, Crosby, Tom, Ting, Yuk, Patel, Kinnari, Sherriff, David, Soomal, Rubin, Borg, David, Sothi, Sharmila, Hammel, Pascal, Lerch, Markus M., Mayerle, Julia, Tjaden, Christine, Strobel, Oliver, Hackert, Thilo, Buchler, Markus W., Neoptolemos, John P., Hill, Mark, Corrie, Pippa, Hickish, Tamas, Napier, Mark, Slater, Sarah, Valle, Juan, Shablak, Alaaeldin, Cunnell, Michelle, Guimbaud, Rosine, Roques, Tom, Iveson, Tim, Jamil, Arshad, Robinson, Angus, Garcia-Alonso, Angel, Chang, David, Tsang, David, Wadd, Nick, Wall, Lucy, Nielsen, Niels Hilmer, Lerch, Markus, Mehta, Ajay, Sivaramalingam, Muthiah, Fyfe, David, Osborne, Richard, Blesing, Claire, Bulusu, Venkata Ramesh, Rathbone, Emma, Seitz, Jean-Francois, Beaumont, Erica, Dernedde, Ulrike, McAdam, Karen, Dimopoulos, Prokopios, Cominos, Mathilda, Askill, Colin, Piwowar, Andrzej, Bachet, Jean-Baptiste, Sumpter, Kate, Raouf, Sherif, Nicoll, Jonathan, Rees, Charlotte, Dhinakaran, Kathirvelu, Haux, Johan, Bengrine-Lefevre, Leila, Terrebonne, Eric, Shankland, Catherine, Palmer, Cheryl, Medley, Louise, Toy, Elizabeth, Kaur, Jasvinder, Gupta, Kamalnayan, Cheeseman, Sue, Patterson, Daniel, Candish, Charles, Thompson, Joyce, Coxon, Fareeda, Connolly, Caroline, McPhail, Neil, Williams, Rachel, Flygare, Petra, Elmlund, Mattias, Artru, Pascal, and Millat, Bertrand

Abstract

Importance: The patterns of disease recurrence after resection of pancreatic ductal adenocarcinoma with adjuvant chemotherapy remain unclear. Objective: To define patterns of recurrence after adjuvant chemotherapy and the association with survival. Design, Setting, and Participants: Prospectively collected data from the phase 3 European Study Group for Pancreatic Cancer 4 adjuvant clinical trial, an international multicenter study. The study included 730 patients who had resection and adjuvant chemotherapy for pancreatic cancer. Data were analyzed between July 2017 and May 2019. Interventions: Randomization to adjuvant gemcitabine or gemcitabine plus capecitabine. Main Outcomes and Measures: Overall survival, recurrence, and sites of recurrence. Results: Of the 730 patients, median age was 65 years (range 37-81 years), 414 were men (57%), and 316 were women (43%). The median follow-up time from randomization was 43.2 months (95% CI, 39.7-45.5 months), with overall survival from time of surgery of 27.9 months (95% CI, 24.8-29.9 months) with gemcitabine and 30.2 months (95% CI, 25.8-33.5 months) with the combination (HR, 0.81; 95% CI, 0.68-0.98; P=.03). The 5-year survival estimates were 17.1% (95% CI, 11.6%-23.5%) and 28.0% (22.0%-34.3%), respectively. Recurrence occurred in 479 patients (65.6%); another 78 patients (10.7%) died without recurrence. Local recurrence occurred at a median of 11.63 months (95% CI, 10.05-12.19 months), significantly different from those with distant recurrence with a median of 9.49 months (95% CI, 8.44-10.71 months) (HR, 1.21; 95% CI, 1.01-1.45; P=.04). Following recurrence, the median survival was 9.36 months (95% CI, 8.08-10.48 months) for local recurrence and 8.94 months (95% CI, 7.82-11.17 months) with distant recurrence (HR, 0.89; 95% CI, 0.73-1.09; P=.27). The median overall survival of patients with distant-only recurrence (23.03 months; 95% CI, 19.55-25.85 months) or local with distant recurrence (23.82 months; 95% CI, 17.48-28.32

Published
2019
Full Text
View/download PDF

41. Le patient âgé connecté dans le cadre du suivi des thérapies orales: Expérience au Centre Georges-François Leclerc, Dijon.

Author

Cadoret, Laëtitia, Schmitt, Antonin, Quipourt, Valérie, Bengrine-Lefevre, Leila, and Dorléan, Christine

Subjects
OLDER patients, CANCER treatment, CANCER patients, MEDICAL prescriptions, NURSES
Abstract

The article examines how elderly patient connect within the framework of the follow-up of oral therapy. It mentions that the center for the fight against cancer Georges-Francois Leclerc (CGFL, Dijon) is a pioneer in providing of patients on oral therapy, with the place of multidisciplinary primary prescription consultations, and also a telephone follow-up weekly by state-certified nurses (IDE), in order to assess the patient's feelings about disease, and the occurrence of side effects.

Published
2020
Full Text
View/download PDF

43. Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX–Bevacizumab Drug Treatment Regimen

Author

Limagne, Emeric, primary, Euvrard, Romain, additional, Thibaudin, Marion, additional, Rébé, Cédric, additional, Derangère, Valentin, additional, Chevriaux, Angélique, additional, Boidot, Romain, additional, Végran, Frédérique, additional, Bonnefoy, Nathalie, additional, Vincent, Julie, additional, Bengrine-Lefevre, Leila, additional, Ladoire, Sylvain, additional, Delmas, Dominique, additional, Apetoh, Lionel, additional, and Ghiringhelli, François, additional

Published
2016
Full Text
View/download PDF

45. Phase II of desynchronized irinotecan plus bevacizumab, oxaliplatin, 5-fluorouracil, and folinic acid (bFOLFIRINOX-3) administration in chemorefractory metastatic colorectal cancer patients.

Author

Fumet, Jean-David, Bertaut, Aurelie, Roussot, Nicolas, Bellio, Hélène, Bengrine-Lefevre, Leila, Vincent, Julie, Niogret, Julie, Palmier, Rémi, Collot, Thomas, Rambach, Laurie, Boudrant, Axelle, Parnalland, Sophie, Rederstorff, Emilie, Hennequin, Audrey, Zanetta, Sylvie, Hervieu, Alice, and Ghiringhelli, François

Published
2023
Full Text
View/download PDF

46. Platinum-sensitivity in metastatic colorectal cancer: Towards a definition

Author

Chibaudel, Benoist, primary, Tournigand, Christophe, additional, Bonnetain, Franck, additional, Maindrault-Goebel, Frédérique, additional, Lledo, Gérard, additional, André, Thierry, additional, Larsen, Annette K., additional, Bengrine-Lefevre, Leila, additional, Louvet, Christophe, additional, and de Gramont, Aimery, additional

Published
2013
Full Text
View/download PDF

47. Efficacy and safety of bevacizumab combined with capecitabine in progressive, metastatic well-differentiated digestive endocrine tumors (BETTER study).

Author

Mitry, Emmanuel, primary, Walter, Thomas, additional, Baudin, Eric, additional, Kurtz, Jean-Emmanuel, additional, Ruszniewski, Philippe, additional, Dominguez, Sophie, additional, Bengrine-Lefevre, Leila, additional, Cadiot, Guilaume, additional, Kraemer, Sandrine, additional, and Ducreux, Michel, additional

Published
2012
Full Text
View/download PDF

48. Simplified Prognostic Model in Patients with Oxaliplatin-Based or Irinotecan-Based First-Line Chemotherapy for Metastatic Colorectal Cancer: A GERCOR Study

Author

Chibaudel, Benoist, primary, Bonnetain, Franck, additional, Tournigand, Christophe, additional, Bengrine-Lefevre, Leila, additional, Teixeira, Luis, additional, Artru, Pascal, additional, Desramé, Jérôme, additional, Larsen, Annette K., additional, André, Thierry, additional, Louvet, Christophe, additional, and Gramont, Aimery, additional

Published
2011
Full Text
View/download PDF

50. PARP inhibitor resistance and TP53 mutations in patients treated with olaparib for BRCA-mutated cancer: Four case reports.

Author

Collot, Thomas, Niogret, Julie, Carnet, Marion, Chevrier, Sandy, Humblin, Etienne, Favier, Laure, Bengrine-Lefevre, Leila, Desmoulins, Isabelle, Arnould, Laurent, and Boidot, Romain

Subjects
POLY(ADP-ribose) polymerase, POLY ADP ribose, BRCA genes, DNA ligases, BIOMARKERS, ADENOSINE diphosphate ribose, P53 antioncogene, BRAF genes, OLAPARIB
Abstract

Loss-of-function BRCA mutations are frequent in high-grade serous ovarian carcinoma. BRCA1 and −2 mutations lead to homologous recombination (HR) deficiency. Poly(ADP-ribose) polymerases (PARP) are enzymes involved in DNA repair. PARP inhibitors (PARPi) lead to DNA damage accumulation in cells deficient in HR. Olaparib (a PARPi) is currently used for the treatment of high-grade serous ovarian carcinoma with germline or somatic BRCA mutations; however, numerous patients do not respond or eventually develop resistance to these agents. The TP53 gene encodes the p53 protein, which is often referred to as the 'guardian of the genome'. TP53 mutations at diagnosis are known to promote resistance to chemotherapy. In the present study, four cases of patients with BRCA-mutated cancer treated with olaparib, who progressed following the PARPi treatment, are reported. Exome analyses were performed on a primary tumor biopsy at diagnosis, then on a progressing metastasis following olaparib treatment. Exome analyses following olaparib treatment identified de novo TP53 mutations, as well as increased frequencies of pre-existing TP53 mutations compared with the primary tumor. In HCT116 TP53−/− cells carrying BRCA2 pathogenic mutations, TP53 inactivating mutations were associated with lower sensitivity to olaparib in vitro. Thus, inactivating TP53 mutations may be associated to olaparib resistance in the presence of BRCA mutations. In conclusion, the present findings demonstrated resistance to PARPi with de novo TP53 mutations that may be clinically relevant. As TP53 mutations are easily detectable with targeted next-generation sequencing panels, these may serve as surrogate markers for the onset of PARPi resistance in the context of routine patient management strategies. [ABSTRACT FROM AUTHOR]

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results